MedTrace Logo

Phase 2 Study of Oral K201 for Prevention of AF Recurrence

NCT01067833 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2011-05-16

No results posted yet for this study

Summary

To evaluate the safety, efficacy, and tolerability of 3 doses of K201 (oral) administered for up to 28 days in subjects with recent DC cardioversion to sinus rhythm from sustained symptomatic atrial fibrillation (AF duration \>3 days and \<6 months).

Conditions

Interventions

DRUG

K201 Tablet

oral tablet, x28 days

DRUG

Placebo Tablet

oral tablet, x28 days

Sponsors & Collaborators

  • Sequel Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Paul Chamberlin, MD · Sequel Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-10-31
Completion
2011-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01067833 on ClinicalTrials.gov